Merck & Co., Inc. (MRK) Income Statement Analysis

See more : Genertec Universal Medical Group Company Limited (2666.HK) Income Statement Analysis – Financial Results

Complete financial analysis of Merck & Co., Inc. (MRK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Merck & Co., Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.

You may be interested

Merck & Co., Inc. (MRK)

Industry: Drug Manufacturers - General

Sector: Healthcare

Website: https://www.merck.com

About Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985
Revenue	60.12B	59.28B	48.70B	41.52B	46.84B	42.29B	40.12B	39.81B	39.50B	42.24B	44.03B	47.27B	48.05B	45.99B	27.43B	23.85B	24.20B	22.64B	22.01B	22.94B	22.49B	51.79B	47.72B	40.36B	32.71B	26.90B	23.64B	19.83B	16.68B	14.97B	10.50B	9.66B	8.60B	7.67B	6.55B	5.94B	5.06B	4.13B	3.55B
Cost of Revenue	16.13B	17.41B	13.63B	13.62B	14.11B	13.51B	12.78B	13.89B	14.93B	16.77B	16.95B	16.45B	16.87B	18.40B	9.02B	5.58B	6.14B	6.00B	5.15B	4.96B	4.32B	33.05B	28.98B	21.17B	16.71B	13.17B	10.95B	8.59B	6.79B	5.28B	2.11B	1.77B	1.67B	1.52B	1.33B	1.32B	1.23B	1.14B	1.09B
Gross Profit	43.99B	41.87B	35.08B	27.90B	32.73B	28.79B	27.35B	25.92B	24.56B	25.47B	27.08B	30.82B	31.18B	27.59B	18.41B	18.27B	18.06B	16.63B	16.86B	17.98B	18.17B	18.74B	18.74B	19.20B	16.01B	13.72B	12.68B	11.24B	9.89B	9.69B	8.39B	7.89B	6.93B	6.15B	5.22B	4.62B	3.83B	2.98B	2.46B
Gross Profit Ratio	73.17%	70.63%	72.02%	67.20%	69.87%	68.06%	68.16%	65.10%	62.19%	60.30%	61.50%	65.21%	64.89%	60.00%	67.12%	76.59%	74.62%	73.49%	76.61%	78.38%	80.81%	36.18%	39.27%	47.56%	48.93%	51.02%	53.66%	56.69%	59.30%	64.72%	79.89%	81.63%	80.57%	80.13%	79.72%	77.76%	75.61%	72.29%	69.28%
Research & Development	30.53B	13.55B	12.25B	13.40B	9.87B	9.75B	9.98B	7.19B	6.70B	7.18B	7.50B	8.17B	8.47B	10.99B	5.85B	4.81B	4.88B	4.78B	3.85B	4.01B	3.18B	2.68B	2.46B	2.34B	2.07B	1.82B	1.68B	1.49B	1.33B	1.23B	1.17B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	8.20B	7.84B	7.63B	7.16B	8.72B	8.00B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	2.30B	2.20B	2.00B	1.80B	1.90B	2.10B	9.83B	9.76B	10.31B	11.61B	11.91B	12.78B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	10.50B	10.04B	9.63B	8.96B	10.62B	10.10B	9.83B	9.76B	10.31B	11.61B	11.91B	12.78B	13.73B	13.25B	8.54B	7.38B	7.56B	8.17B	7.16B	7.35B	6.39B	6.19B	6.22B	6.17B	5.20B	4.51B	4.30B	3.84B	3.30B	3.18B	2.91B	4.07B	3.56B	3.24B	2.76B	2.55B	2.25B	1.75B	1.33B
Other Expenses	0.00	960.00M	468.00M	469.00M	-139.00M	849.00M	304.00M	-357.00M	-72.00M	12.00B	12.00M	44.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	40.91B	23.59B	21.88B	22.35B	20.49B	19.85B	19.81B	16.96B	17.02B	18.79B	19.41B	20.94B	22.20B	24.24B	14.39B	12.18B	12.44B	12.95B	11.00B	11.36B	9.71B	9.07B	9.01B	10.11B	8.41B	7.35B	7.02B	6.26B	5.49B	5.28B	4.50B	4.40B	3.82B	3.50B	2.99B	2.75B	2.46B	1.94B	1.62B
Cost & Expenses	57.16B	41.00B	35.51B	35.97B	34.60B	33.36B	32.59B	30.85B	31.95B	35.55B	36.37B	37.39B	39.07B	42.63B	23.41B	17.76B	18.58B	18.95B	16.15B	16.32B	14.03B	42.12B	37.99B	31.27B	25.12B	20.52B	17.97B	14.84B	12.28B	10.56B	6.61B	6.17B	5.49B	5.02B	4.31B	4.07B	3.69B	3.09B	2.71B
Interest Income	365.00M	157.00M	36.00M	59.00M	274.00M	343.00M	385.00M	328.00M	289.00M	266.00M	264.00M	232.00M	199.00M	83.00M	210.20M	631.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	1.15B	962.00M	806.00M	831.00M	893.00M	772.00M	754.00M	693.00M	672.00M	732.00M	801.00M	714.00M	749.00M	715.00M	458.00M	251.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	3.87B	3.91B	3.21B	3.49B	3.65B	4.52B	4.64B	5.44B	6.38B	6.69B	6.99B	6.98B	7.43B	7.38B	2.58B	1.63B	1.99B	2.27B	1.71B	1.45B	1.31B	1.49B	1.46B	1.28B	1.14B	1.02B	1.03B	927.10M	859.20M	875.50M	414.70M	321.40M	263.80M	254.00M	221.70M	204.90M	210.00M	193.90M	182.50M
EBITDA	6.91B	21.32B	17.90B	10.18B	16.01B	13.99B	11.95B	10.79B	12.45B	24.71B	13.33B	16.43B	15.51B	9.75B	18.33B	11.81B	13.06B	5.98B	7.75B	7.58B	9.44B	11.07B	10.94B	9.63B	7.54B	5.27B	5.64B	5.07B	4.68B	5.05B	4.95B	3.74B	3.32B	2.86B	2.41B	2.07B	1.54B	1.13B	936.90M
EBITDA Ratio	11.49%	39.32%	34.73%	23.03%	27.50%	24.24%	20.60%	22.65%	20.18%	45.48%	18.95%	22.84%	20.37%	24.80%	-18.28%	28.56%	53.99%	26.43%	35.22%	33.05%	41.98%	21.37%	22.92%	23.85%	23.05%	19.58%	23.88%	25.58%	28.05%	33.75%	47.14%	38.71%	38.55%	37.25%	36.81%	34.81%	30.49%	27.47%	26.41%
Operating Income	2.95B	19.40B	13.70B	6.08B	9.23B	5.73B	3.63B	3.58B	1.59B	12.52B	1.36B	3.82B	2.36B	4.03B	-7.59B	5.18B	11.08B	3.71B	6.04B	6.13B	8.13B	9.58B	9.47B	8.35B	6.39B	4.25B	4.61B	4.15B	3.82B	4.18B	4.53B	3.42B	3.05B	2.60B	2.19B	1.86B	1.33B	940.20M	754.40M
Operating Income Ratio	4.91%	32.72%	28.14%	14.63%	19.70%	13.55%	9.04%	8.98%	4.04%	29.64%	3.08%	8.08%	4.91%	8.75%	-27.67%	21.72%	45.77%	16.41%	27.46%	26.73%	36.14%	18.50%	19.86%	20.69%	19.55%	15.80%	19.50%	20.91%	22.90%	27.90%	43.19%	35.39%	35.49%	33.94%	33.43%	31.36%	26.34%	22.77%	21.27%
Total Other Income/Expenses	-1.07B	-1.84B	680.00M	315.00M	3.54B	-230.00M	-986.00M	1.08B	-2.15B	4.77B	-2.12B	-1.14B	-1.64B	-1.70B	11.27B	3.85B	-2.25B	2.63B	1.44B	530.90M	926.30M	632.60M	927.90M	735.00M	2.23B	3.88B	1.85B	1.40B	977.80M	238.00M	-783.00M	144.20M	114.00M	94.80M	93.40M	8.40M	72.00M	133.10M	102.60M
Income Before Tax	1.89B	16.44B	13.88B	8.79B	11.46B	8.70B	6.75B	7.50B	5.40B	17.28B	5.55B	9.23B	7.33B	1.65B	15.29B	9.81B	3.37B	6.22B	7.36B	7.97B	9.05B	10.21B	10.40B	9.82B	8.62B	8.13B	6.46B	5.54B	4.80B	4.42B	3.10B	3.56B	3.17B	2.70B	2.28B	1.87B	1.41B	1.07B	857.00M
Income Before Tax Ratio	3.14%	27.74%	28.50%	21.17%	24.47%	20.57%	16.82%	18.84%	13.67%	40.92%	12.59%	19.53%	15.26%	3.59%	55.75%	41.12%	13.93%	27.48%	33.45%	34.76%	40.25%	19.72%	21.80%	24.34%	26.35%	30.24%	27.34%	27.94%	28.76%	29.49%	29.55%	36.88%	36.81%	35.18%	34.85%	31.50%	27.76%	25.99%	24.16%
Income Tax Expense	1.51B	1.92B	1.52B	1.71B	1.69B	2.51B	4.16B	1.79B	942.00M	5.35B	1.03B	2.44B	942.00M	671.00M	2.27B	2.00B	95.30M	1.79B	2.73B	2.16B	2.46B	3.06B	3.12B	3.00B	2.73B	2.88B	1.85B	1.66B	1.46B	1.42B	936.50M	1.12B	1.05B	917.60M	787.60M	664.20M	498.80M	397.60M	317.10M
Net Income	365.00M	14.52B	13.05B	7.07B	9.84B	6.22B	2.57B	5.69B	4.44B	11.92B	4.40B	6.66B	6.27B	861.00M	12.90B	7.81B	3.28B	4.43B	4.63B	5.81B	6.83B	7.15B	7.28B	6.82B	5.89B	5.25B	4.61B	3.88B	3.34B	3.00B	2.17B	1.98B	2.12B	1.78B	1.50B	1.21B	906.40M	675.70M	539.90M
Net Income Ratio	0.61%	24.49%	26.79%	17.02%	21.01%	14.71%	6.40%	14.30%	11.25%	28.22%	10.00%	14.09%	13.05%	1.87%	47.04%	32.74%	13.54%	19.59%	21.04%	25.34%	30.38%	13.80%	15.26%	16.90%	18.01%	19.51%	19.52%	19.57%	19.99%	20.02%	20.63%	20.54%	24.66%	23.22%	22.83%	20.32%	17.91%	16.37%	15.22%
EPS	0.14	5.73	5.16	2.79	3.84	2.40	0.95	2.07	1.60	4.20	1.50	2.20	2.06	0.28	4.15	3.65	-1.04	2.04	2.11	2.63	2.97	3.17	3.18	2.96	2.51	2.21	1.92	1.60	1.35	1.19	0.94	1.06	0.92	0.76	0.63	0.51	0.37	0.27	0.21
EPS Diluted	0.14	5.71	5.14	2.78	3.82	2.32	0.93	2.04	1.56	4.07	1.47	2.16	2.02	0.28	4.15	3.63	-1.04	2.03	2.10	2.62	2.97	3.14	3.14	2.90	2.45	2.15	1.87	1.56	1.32	1.18	0.93	1.05	0.91	0.76	0.63	0.51	0.37	0.27	0.21
Weighted Avg Shares Out	2.61B	2.53B	2.53B	2.53B	2.57B	2.59B	2.70B	2.75B	2.78B	2.84B	2.93B	3.03B	3.04B	3.10B	2.11B	2.14B	2.17B	2.18B	2.20B	2.22B	2.24B	2.26B	2.29B	2.31B	2.35B	2.37B	2.40B	2.43B	2.47B	2.51B	2.30B	1.87B	2.31B	2.34B	2.37B	2.37B	2.45B	2.50B	2.57B
Weighted Avg Shares Out (Dil)	2.55B	2.54B	2.54B	2.54B	2.58B	2.68B	2.75B	2.79B	2.84B	2.93B	3.00B	3.08B	3.09B	3.12B	2.27B	2.14B	2.19B	2.19B	2.20B	2.23B	2.25B	2.28B	2.32B	2.35B	2.40B	2.44B	2.47B	2.49B	2.54B	2.55B	2.33B	1.89B	2.33B	2.34B	2.37B	2.37B	2.45B	2.50B	2.57B

Buy 3 November Dogs Of The Dow And Watch 7 More

November 2, 2024seekingalpha.com

"The Dow® [adds a stock] if the company has an excellent reputation,

Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease

November 1, 2024benzinga.com

On Thursday, Merck & Co Inc MRK reported third-quarter sales of $16.66 billion, up 4% year over year, beating the consensus of $16.47 billion.

Is Merck Stock a Buy?

November 1, 2024fool.com

The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better.

Merck & Co., Inc. (MRK) Q3 2024 Earnings Conference Call Transcript

October 31, 2024seekingalpha.com

Start Time: 09:00 January 1, 0000 10:00 AM ET Merck & Co., Inc. (NYSE:MRK ) Q3 2024 Earnings Call October 31, 2024, 09:00 AM ET Company Participants Peter Dannenbaum - SVP, IR Rob Davis - Chairman and CEO Caroline Litchfield...

Merck Q3 Earnings & Sales Top, Stock Down on Lowered '24 View

October 31, 2024zacks.com

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales performance of the Gardasil vaccines.

Merck (MRK) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

October 31, 2024zacks.com

While the top- and bottom-line numbers for Merck (MRK) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates...

Merck (MRK) Q3 Earnings and Revenues Top Estimates

October 31, 2024zacks.com

Merck (MRK) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.50 per share. This compares to earnings of $2.13 per share a year ago.

Merck CEO Robert Davis on Q3 results: Our portfolio sets us up for a good finish to the year

October 31, 2024youtube.com

Merck CEO Robert Davis joins 'Squawk Box' to discuss the company's quarterly earnings results, which topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business, the company's drug...

Merck tops estimates despite muted Gardasil and diabetes drug sales

October 31, 2024proactiveinvestors.com

Merck & Co Inc (NYSE:MRK, ETR:6MK) has topped third-quarter estimates despite flagging sales of its Gardasil jab, diabetes drugs and Covid-19 treatment. Revenue for the three months to September climbed by 4% to $16.66 billion, the pharmaceutical firm reported on...